Position:
Clinical Professor
Division:
Hematology
Research Interests:

Major interests have included the chemotherapy of acute myeloid leukemia with a sub interest in the therapy of acute myeloid leukemia in elderly patients; the use of autologous and allogeneic bone marrow transplantation in non-leukemic lymphoid malignancies (non-Hodgkin’s lymphoma, multiple myeloma, chronic lymphocytic leukemia); and the supportive care of patients undergoing intensive therapy with bone marrow support.

Education:
BSc (Honours) University of British Columbia Microbiology
MD University of Calgary
MSc University of Calgary Biochemistry/Medical Science
Recent Publications:
  • Baker A, Beed S, Fenwick J, Kjerulf M, Bell H, Logier S, Shepherd J.  Number of deaths by neurological criteria, and organ and tissue donation rates at three critical care centres in Canada: [Le nombre de morts salon des criteres neurologiques et les taux de dons d’organes et de tissue dans trois centres de soins intensifs au Canada]. Can J Anaesth 53:722-726, 2006.
  • Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielson JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 355(23):2408-17, 2006.
  • Johny A, Song KW, Nantel SH, Lavoie JC, Toze CL, Hogge DE, Forrest DL, Sutherland HJ, Le A, Nitta JY, Barnett MJ, Smith CA, Shepherd JD, Nevill TJ.  Early stem cell transplantation for Refractory Acute Leukemia after Salvage Therapy with High-Dose Etoposide and Cyclophosphamide. Biol Blood Marrow Transplant 12: 480-489, 2006.
  • Lin Y, Bruyere H, Horsman DE, Pantzar T, Barnett MJ, Hogge DE, Nevill TJ, Nantel SH, Sutherland HJ, Toze CL, Shepherd JD, Lavoie JC, Song KW, Smith CA, Forrest DL. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors. Cancer Genet Cytogenet 170: 16-23, 2006.
  • Savoie ML, Nevill TJ, Song KW, Forrest DL, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL & Lavoie JC. Shifting to outpatient management of acute myeloid leukemia: A prospective experience. Ann Oncol 17:731-732, 2006.
  • Song KW, Barnett MJ, Gascoyne RD, Horsman DE, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Voss NJ, Toze CL, Connors JM. Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma. Br J Haematol 133: 634-637, 2006.
  • Druker BJ, Guilhot, F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MWN, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA. Five-year follow-up of patients receiving Imatinib for Chronic Myeloid Leukemia.  N Engl J Med 355:2408-17, 2006.
  • Halim TY, Song KW, Barnett MJ, Forrest DL, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Lavoie JC Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septicemia. Ann Oncol 18(7): 1246-52, 2007.
  • Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 13(8): 925-31, 2007.
  • Song K, Barnett M, Gascoyne R, Chhanabhai M, Forrest D, Hogge D, Lavoie J, Nantel S, Nevill T, Shepherd J, Smith C, Toze C, Voss N, Connors J.  Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic step-cell transplantation results in favorable outcomes. Ann Oncol 18: 535-540, 2007.
  • Forrest DL, Trainor S, Brinkman RR, Barnett MJ, Hogge DE, Nevill TJ, Shepherd JD, Nantel SH, Toze CL, Sutherland HJ, Song KW, Lavoie JC, Power MM, Abou-Mourad Y, Smith CA. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res 33(2):271-5, 2009.
  • Irvine DA, Shepherd JD. Recurrence of lymphoid blast crisis over 20 years after successful sibling allo-SCT for CML: short lived complete cytogenetic response to imatinib. Bone Marrow Transplant 44(4):267-8, 2009.
  • Nevill TJ, Shepherd JD, Sutherland HJ, Abou Mourad YR, Lavoie JC, Barnett MJ, Nantel SH, Toze CL, Hogge DE, Forrest DL, Song KW, Power MM, Nitta JY, Dai Y, Smith CA. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation. Biol Blood Marrow Transplant 15(2):205-13, 2009.
  • Wright MP, Shepherd JD, Barnett MJ, Nantel SH, Sutherland HJ, Toze CL, Hogge DE, Nevill TJ, Song KW, Abou Mourad YR, Narayanan S, Power MM, Smith CA, Forrest DL. Response to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia Relapsing in Chronic and Advanced Phase Following Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2009 [Epub ahead of print].
  • Abou-Mourad YR, Lau BC, Barnett MJ, Forrest DL, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Lavoie JC. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplant. 2010 Feb;45(2):295-302.
  • Wright MP, Shepherd JD, Barnett MJ, Nantel SH, Sutherland HJ, Toze CL, Hogge DE, Nevill TJ, Song KW, Abou Mourad YR, Narayanan S, Power MM, Smith CA, Forrest DL. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010 May;16(5):639-46.
  • Sharpe R, Koval V, Ronco JJ, Qayumi K, Dodek P, Wong H, Shepherd J, FitzGerald JM, Ayas NT. The Impact of Prolonged Continuous Wakefulness on Resident Clinical Performance in the Intensive Care Unit: A Patient Simulator Study. Critical Care Medicine 38:766-770, 2010.